212 related articles for article (PubMed ID: 15171712)
1. Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
Maggiolini M; Recchia AG; Carpino A; Vivacqua A; Fasanella G; Rago V; Pezzi V; Briand PA; Picard D; Andò S
J Mol Endocrinol; 2004 Jun; 32(3):777-91. PubMed ID: 15171712
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
4. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor β exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
Chaurasiya S; Widmann S; Botero C; Lin CY; Gustafsson JÅ; Strom AM
PLoS One; 2020; 15(5):e0226057. PubMed ID: 32413024
[TBL] [Abstract][Full Text] [Related]
6. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
8. Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.
Hess-Wilson JK; Webb SL; Daly HK; Leung YK; Boldison J; Comstock CE; Sartor MA; Ho SM; Knudsen KE
Environ Health Perspect; 2007 Nov; 115(11):1646-53. PubMed ID: 18007998
[TBL] [Abstract][Full Text] [Related]
9. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
[TBL] [Abstract][Full Text] [Related]
10. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
[TBL] [Abstract][Full Text] [Related]
11. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
[TBL] [Abstract][Full Text] [Related]
12. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
13. Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.
Yang L; Ravindranathan P; Ramanan M; Kapur P; Hammes SR; Hsieh JT; Raj GV
Mol Endocrinol; 2012 Apr; 26(4):550-61. PubMed ID: 22403175
[TBL] [Abstract][Full Text] [Related]
14. A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer.
Krishnan AV; Zhao XY; Swami S; Brive L; Peehl DM; Ely KR; Feldman D
Endocrinology; 2002 May; 143(5):1889-900. PubMed ID: 11956172
[TBL] [Abstract][Full Text] [Related]
15. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
16. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
17. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
18. Enhanced formation of non-phenolic androgen metabolites with intrinsic oestrogen-like gene transactivation potency in human breast cancer cells: a distinctive metabolic pattern.
Pérez-Palacios G; Santillán R; García-Becerra R; Borja-Cacho E; Larrea F; Damián-Matsumura P; González L; Lemus AE
J Endocrinol; 2006 Sep; 190(3):805-18. PubMed ID: 17003281
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Culig Z; Hobisch A; Cronauer MV; Radmayr C; Trapman J; Hittmair A; Bartsch G; Klocker H
Cancer Res; 1994 Oct; 54(20):5474-8. PubMed ID: 7522959
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.
Benbrahim-Tallaa L; Webber MM; Waalkes MP
Environ Health Perspect; 2005 Sep; 113(9):1134-9. PubMed ID: 16140617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
